Back to VVUS Stock Lookup

VVUS – Analyst Ratings

Apr 11, 2014 06:30 AM Vivus (VVUS) Qsymia Numbers Lowered at Needham & Company
Apr 3, 2014 10:48 AM Piper Cuts VIVUS, Inc. (VVUS) to Underweight; Proxy Battles Weigh on Outlook
Apr 3, 2014 06:35 AM Piper Jaffray Downgrades Vivus (VVUS) to Underweight
Feb 25, 2014 08:31 AM Vivus (VVUS) Qsymia Sales Lackluster and Partner Continues to be a Challenge: Needham & Company
Feb 25, 2014 07:57 AM JPMorgan Downgrades Vivus (VVUS) to Neutral
Feb 25, 2014 07:01 AM BofA/Merrill Lynch Downgrades Vivus (VVUS) to Underperform
Jan 10, 2014 02:34 PM WallachBeth Starts Orexigen (OREX) at Buy; Sees Contrave With Edge Over Peers (ARNA) (VVUS)
Dec 27, 2013 12:20 PM VIVUS (VVUS) Low-Dose Qsymia TRx Fell 6% Last Week, Off 40% from Peak (ARNA)
Dec 12, 2013 08:24 AM Analyst Sees Positive Reimbursement Trends for Obesity Drugs (VVUS) (ARNA) (OREX)
Nov 27, 2013 12:04 PM Recent Contrave Data is Positive for Orexigen's (OREX) Other Weight-Loss Candidate - Analyst
Nov 25, 2013 09:43 AM Aegis Capital Boosts PT on Auxilium (AUXL) to $33; Xiaflex Bear Case Just Doesn't Play Out
Nov 18, 2013 02:56 PM Challenge from Arena's (ARNA) Bel-Phen Could Limit Upside in VIVUA (VVUS) - Analyst
Nov 15, 2013 09:09 AM IMS Script Data for Nov 8th (BIIB) (VVUS) (ARNA)
Nov 15, 2013 06:21 AM WallachBeth Capital Starts VIVUS (VVUS) at Hold
Nov 6, 2013 07:13 AM BofA/Merrill Lynch Downgrades Vivus (VVUS) to Neutral
Nov 1, 2013 08:56 AM IMS Script Data for Oct. 25th (BIIB) (VVUS) (ARNA)
Oct 25, 2013 12:04 PM Arena's (ARNA) Belviq TRx Growth Outpaced VIVUS' (VVUS) Qsymia Last Week - Analyst
Oct 16, 2013 08:42 AM UPDATE: Piper Jaffray Downgrades Vivus (VVUS) to Neutral
Oct 11, 2013 10:51 AM Vivus (VVUS) Inks Stendra Deal as Qsymia Gains Traction - Leerink Swann Comments
Oct 3, 2013 07:32 AM Cowen Upgrades Vivus (VVUS) to Outperform
Oct 3, 2013 07:31 AM Leerink Keeps VIVUS, Inc. (VVUS) at Outperform; Expects Mid-Oct. Qsymia Update
Oct 2, 2013 08:31 AM Vivus (VVUS) Partner Talks Going Well, CEO Tells BofA ML
Sep 12, 2013 09:16 AM Vivus (VVUS) Target Lowered to $14 from $20 at Piper
Sep 4, 2013 07:33 AM Lazard Capital Downgrades Vivus (VVUS) to Sell
Aug 23, 2013 08:56 AM Arena (ARNA) Belviq TRx Growth Outpaced Vivus (VVUS) Qsymia Last Week
Jul 19, 2013 02:20 PM Analyst Notes Encouraging Scripts Trends for Vivus's (VVUS) Qsymia
Jul 19, 2013 10:50 AM Needham & Company Downgrades Vivus (VVUS) to Hold; Sees Disruption Following Settlement
Jul 15, 2013 06:36 AM Credit Suisse Downgrades Vivus (VVUS) to Neutral
Jul 9, 2013 02:45 PM Analyst Scoffs at Vivus (VVUS) / Menarini Agreement
Jun 19, 2013 12:23 PM Bill for Medicare Coverage, AMA Designation Positive for Obesity Drug Makers (ARNA) (VVUS) (OREX) - Leerink Swann
Jun 18, 2013 08:09 AM VIVUS (VVUS) Qsymia Prescriptions Fall Ahead of Belviq Launch (ARNA)
May 28, 2013 02:30 PM Leerink Swann Positive on Vivus (VVUS); Warns Not to Misinterpret IMS Script Data
May 28, 2013 11:36 AM Piper Jaffray Says Vivus (VVUS) May Find Partner Before End of Year
May 14, 2013 07:35 AM UPDATE: Lazard Capital Downgrades Vivus (VVUS) to Neutral
May 8, 2013 03:06 PM Brean Capital Maintains Sell of Vivus (VVUS), Notes Slower April Growth
Apr 30, 2013 10:58 AM VIVUS (VVUS) Inks Qsymia Deal with MEDCO; 'Executing Well' Says Analyst
Apr 17, 2013 08:44 AM Jefferies Remains Cautious on Vivus (VVUS) Despite Qsymia REMS Expansion
Apr 9, 2013 03:33 PM VIVUS, Inc. (VVUS) Positive; Shorts Cover Into REMS Modification for Qsymia
Mar 27, 2013 08:21 AM Leerink Swann Reiterates Outperform on VIVUS (VVUS), Review in Health Economics A Positive
Mar 26, 2013 12:56 PM Vivus (VVUS) Financing Agreement Does Not Appear Cheap - Analyst
Mar 5, 2013 04:18 PM Piper Jaffray Starts Vivus (VVUS) at Overweight, PT of $17
Mar 4, 2013 02:18 PM Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
Mar 4, 2013 10:08 AM VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
Feb 26, 2013 09:23 AM VIVUS, Inc. (VVUS) Misses Q4 Views on Heftier Qsymia Costs; Analysts Comment
Feb 26, 2013 08:21 AM Needham & Company Sees 2nd-Half Qsymia Ramp for Vivus (VVUS)
Feb 25, 2013 01:15 PM Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
Feb 6, 2013 07:17 AM Leerink Swann Resumes Vivus (VVUS) at Outperform, $19-$20 Valuation
Feb 4, 2013 10:45 AM VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
Jan 17, 2013 07:41 AM Brean Capital Downgrades Vivus (VVUS) to Sell, Low Qsymia Coverage Means Low Sales
Jan 7, 2013 06:50 AM BofA/Merrill Lynch added Vivus (VVUS) to U.S. 1 List

Back to VVUS Stock Lookup